0001564590-21-026300.txt : 20210511 0001564590-21-026300.hdr.sgml : 20210511 20210511080626 ACCESSION NUMBER: 0001564590-21-026300 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210511 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210511 DATE AS OF CHANGE: 20210511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Unity Biotechnology, Inc. CENTRAL INDEX KEY: 0001463361 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264726035 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38470 FILM NUMBER: 21909697 BUSINESS ADDRESS: STREET 1: 3280 BAYSHORE BOULEVARD CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: (415) 328-5504 MAIL ADDRESS: STREET 1: 3280 BAYSHORE BOULEVARD CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: Cenexys, Inc. DATE OF NAME CHANGE: 20130703 FORMER COMPANY: FORMER CONFORMED NAME: Forge Inc DATE OF NAME CHANGE: 20090504 8-K 1 ubx-8k_20210511.htm 8-K ubx-8k_20210511.htm
false 0001463361 0001463361 2021-05-11 2021-05-11

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 11, 2021

 

 

UNITY BIOTECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

001-38470

 

26-4726035

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

285 East Grand Ave.

South San Francisco, CA 94080

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (650) 416-1192

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

UBX

The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

 

Item 2.02

Results of Operations and Financial Condition.

On May 11, 2021, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2021. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K, including the attached Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

Reference is made to the Exhibit Index attached hereto.

 

 

EXHIBIT INDEX

 

Exhibit No.

  

Description

 

 

 

99.1

  

Press release dated May 11, 2021.

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

UNITY BIOTECHNOLOGY, INC.

 

 

 

Date: May 11, 2021

By:

/s/ Anirvan Ghosh

 

 

Anirvan Ghosh, Ph.D.

 

 

Chief Executive Officer

 

 EX-99.1 2 ubx-ex991_6.htm EX-99.1 ubx-ex991_6.htm

Exhibit 99.1

UNITY Biotechnology, Inc. Reports First Quarter 2021 Financial Results and Business Updates

- UBX1325 demonstrates favorable tolerability in Phase 1 safety study with initial evidence of relevant biological activity

 

- Phase 2a proof-of-concept study initiated in patients with diabetic macular edema; data expected first half of 2022

 

- Cash balance sufficient to fund operations into second half of 2022

SOUTH SAN FRANCISCO, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2021.

“The highlight of the quarter was the completion of the initial assessment of patients in our Phase 1 safety study of UBX1325, a senolytic molecule that has the potential to promote reparative vascular remodeling in the retina in various age-related eye diseases such as diabetic macular edema and age-related macular degeneration and could provide a disease-modifying alternative to current VEGF-targeting therapies,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “We are excited by this safety and tolerability data as well as initial evidence of relevant biological activity, and are very pleased to have initiated a Phase 2a proof-of-concept study of UBX1325.”

Key Business Highlights

Ophthalmology – UBX1325

In October 2020, UNITY began its Phase 1 study of UBX1325 in patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The ongoing Phase 1 study includes patients with a diagnosis of DME or AMD with significant visual impairment and who are no longer candidates for anti-vascular endothelial growth factor (VEGF) therapy. UBX1325, the first senolytic agent to be administered to these patient populations, has been well tolerated with no significant treatment-associated adverse events in either disease population.

The initial assessment of the Phase 1, first-in-human, open-label, single-ascending dose study included 12 patients with advanced DME or wet AMD. The primary outcome measure is ocular and systemic safety and tolerability of a single intravitreal injection of UBX1325 evaluated by the incidence of dose limiting toxicities (DLTs) and treatment emergent adverse events (TEAEs) reported up to 24 weeks after administration. The single intravitreal injection of UBX1325 was well tolerated and had no adverse findings that would limit advancement of UBX1325 into further clinical investigation. Based on prospectively determined safety criteria, the Phase 1 study was able to dose-escalate beyond the originally planned 5 mcg dose up to 10 mcg, which will inform the final dose for the Phase 2a study in DME which is expected to read out in 2022. In addition, based on encouraging early data, UNITY intends to recruit additional patients with wet AMD into the Phase 1 study to potentially support an additional, independent Phase 2a study in wet AMD, which could also read out in 2022. The company intends to share details of the activity profile of UBX1325 from this Phase 1 study, including data on best-corrected visual acuity (BCVA), central subfield thickness (CST), and sub-retinal fluid (SRF), in the coming months.

Based on this initial data, UNITY has initiated a Phase 2a proof-of-concept study to evaluate the safety, efficacy, and durability of a single intravitreal injection of UBX1325 in a broader population of patients with DME. Approximately 60 patients will be enrolled in the study, randomized evenly between UBX1325 and sham-injected patients, and followed for 24 weeks post-injection. Endpoints being explored in the study include safety and tolerability, improvements in BCVA, CST, SRF, and durability of effect. UNITY anticipates receiving initial results from the Phase 2a proof-of-concept study in patients with DME in the first of half of 2022.

 

“Mounting evidence shows an accumulation of senescent cells in diseased retinal and choroidal tissue associated with the vasculature – hallmarks of diabetic eye disease and other age-related eye diseases,” said Jamie Dananberg, M.D., chief medical officer of UNITY. “Senolytics represent a potential new class of medicine designed to selectively target diseased blood vessels to reduce vascular leakage, allow healthy vascular remodeling, and restore retinal function. We find the data we have seen to date very promising and look forward to evaluating both the safety and efficacy of UBX1325 in advanced clinical studies.”

Operational Highlights

First Quarter Financial Results

Cash, cash equivalents, and marketable securities totaled $110.2 million as of March 31, 2021 compared with $115.6 million as of December 31, 2020. UNITY believes that current cash, cash equivalents, and marketable securities are sufficient to fund operations into the second half of 2022.

Operating loss for the three months ended March 31, 2021 was $14.9 million compared to $27.2 million for the three months ended March 31, 2020. Cash used in operations during the first quarter of 2021 was $15.1 million compared to $25.1 million for the first quarter of 2020.

Research and development expenses decreased by $10.6 million, to $8.7 million for the three months ended March 31, 2021, from $19.3 million for the three months ended March 31, 2020. The decrease was primarily due to decreases of $6.0 million in direct research and development expenses due to termination of osteoarthritis studies, $2.8 million in personnel costs due to reduction in force, $0.9 million in laboratory supplies, and $0.9 million in facilities-related costs.

General and administrative expenses increased by $0.3 million, to $6.2 million for the three months ended March 31, 2021, from $5.9 million for the three months ended March 31, 2020. The increase was primarily due to increases of $0.4 million in facilities-related costs and $0.1 million in insurance-related expense, offset by a decrease of $0.2 million in professional fees.

About UNITY

UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

 

 

 

About UBX1325

 

UBX1325 is an investigational compound being studied for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR). UBX1325 is a potent small molecule inhibitor of Bcl-xL, a member of the Bcl-2 family of apoptosis-regulatory proteins. UBX1325 is designed to inhibit the function of proteins senescent cells rely on for survival. In preclinical studies, UNITY has demonstrated that targeting Bcl-xL with UBX1325 preferentially eliminates senescent cells from diseased tissue while sparing healthy cells. UNITY’s goal with UBX1325 is to transformationally improve real-world outcomes for patients with DME, AMD, and DR.

 

Forward-Looking Statements

 

This press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to slow, halt, or reverse diseases of aging, including for ophthalmologic and neurologic diseases, our expectations regarding potential benefits, activity, effectiveness, and safety of UBX1325, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for DME, AMD, and other ophthalmologic diseases, the expected timing of results of our studies of UBX1325, the timing of the expected commencement, progression, and conclusion of our studies including those of UBX1325, and UNITY’s expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in clinical trials, risks relating to the uncertainties inherent in the drug development process, and risks relating to UNITY’s understanding of senescence biology. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of UNITY in general, see UNITY’s most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed with the Securities and Exchange Commission on May 11, 2021, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.

 

 

Unity Biotechnology, Inc.

Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2021

 

 

2020

 

 

 

(Unaudited)

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

$

8,717

 

 

$

19,265

 

General and administrative

 

 

6,226

 

 

 

5,953

 

Change in fair value of contingent consideration

 

 

—

 

 

 

(221

)

Impairment of long-lived assets

 

 

—

 

 

 

2,159

 

Total operating expenses

 

 

14,943

 

 

 

27,156

 

Loss from operations

 

 

(14,943

)

 

 

(27,156

)

Interest income

 

 

36

 

 

 

527

 

Interest expense

 

 

(775

)

 

 

—

 

Other expense

 

 

(74

)

 

 

(1,409

)

Net loss

 

 

(15,756

)

 

 

(28,038

)

Other comprehensive loss

 

 

 

 

 

 

 

 

Unrealized gain on marketable debt securities

 

 

10

 

 

 

283

 

Comprehensive loss

 

$

(15,746

)

 

$

(27,755

)

Net loss per share, basic and diluted

 

$

(0.29

)

 

$

(0.59

)

Weighted-average number of shares used in

   computing net loss per share, basic and

   diluted

 

 

54,169,349

 

 

 

47,544,401

 

 

 

 

Unity Biotechnology, Inc.

Condensed Balance Sheets

(In thousands)

 

 

 

March 31,

 

 

December 31,

 

 

 

2021

 

 

2020

 

 

 

(Unaudited)

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

26,842

 

 

$

17,807

 

Short-term marketable securities

 

 

73,617

 

 

 

79,892

 

Prepaid expenses and other current assets

 

 

1,582

 

 

 

3,167

 

Total current assets

 

 

102,041

 

 

 

100,866

 

Property and equipment, net

 

 

11,941

 

 

 

12,627

 

Operating lease right-of-use assets

 

 

22,967

 

 

 

23,509

 

Long-term marketable securities

 

 

9,790

 

 

 

17,871

 

Restricted cash

 

 

1,446

 

 

 

1,446

 

Total assets

 

$

148,185

 

 

$

156,319

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

1,975

 

 

$

2,558

 

Accrued compensation

 

 

1,839

 

 

 

5,355

 

Accrued and other current liabilities

 

 

6,455

 

 

 

6,550

 

Total current liabilities

 

 

10,269

 

 

 

14,463

 

Operating lease liability, net of current portion

 

 

33,264

 

 

 

34,468

 

Long-term debt, net

 

 

24,699

 

 

 

24,508

 

Total liabilities

 

 

68,232

 

 

 

73,439

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Common stock

 

 

5

 

 

 

5

 

Additional paid-in capital

 

 

435,198

 

 

 

422,379

 

Related party promissory notes for purchase

   of common stock

 

 

—

 

 

 

(210

)

Promissory notes for purchase of common stock

 

 

(210

)

 

 

—

 

Accumulated other comprehensive gain

 

 

15

 

 

 

5

 

Accumulated deficit

 

 

(355,055

)

 

 

(339,299

)

Total stockholders’ equity

 

 

79,953

 

 

 

82,880

 

Total liabilities and stockholders’ equity

 

$

148,185

 

 

$

156,319

 

 

 

 


 

Media

Canale Communications

Jason Spark

jason.spark@canalecomm.com

 

 EX-101.SCH 3 ubx-20210511.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 ubx-20210511_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer EX-101.PRE 5 ubx-20210511_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 ubx-8k_20210511_htm.xml IDEA: XBRL DOCUMENT 0001463361 2021-05-11 2021-05-11 false 0001463361 8-K 2021-05-11 UNITY BIOTECHNOLOGY, INC. DE 001-38470 26-4726035 285 East Grand Ave. South San Francisco CA 94080 650 416-1192 false false false false Common Stock, par value $0.0001 per share UBX NASDAQ true false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information
May 11, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 11, 2021
Trading Symbol UBX
Entity Registrant Name UNITY BIOTECHNOLOGY, INC.
Entity Central Index Key 0001463361
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity File Number 001-38470
Entity Tax Identification Number 26-4726035
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 285 East Grand Ave.
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 416-1192
Title of 12(b) Security Common Stock, par value $0.0001 per share
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ubx-8k_20210511.htm ubx-20210511.xsd ubx-20210511_lab.xml ubx-20210511_pre.xml ubx-ex991_6.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ubx-8k_20210511.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "ubx-8k_20210511.htm" ] }, "labelLink": { "local": [ "ubx-20210511_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "ubx-20210511_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "ubx-20210511.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ubx", "nsuri": "http://unitybiotechnology.com/20210511", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "ubx-8k_20210511.htm", "contextRef": "C_0001463361_20210511_20210511", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "ubx-8k_20210511.htm", "contextRef": "C_0001463361_20210511_20210511", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://unitybiotechnology.com/20210511/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001564590-21-026300-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-026300-xbrl.zip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end